Stable liquid preparations containing botulinum toxin
A stable liquid botulinum toxin formulation with proline and optional excipients addresses protein instability issues, providing consistent activity and reducing rehydration errors, enhancing usability and stability.
Patent Information
- Application Number
- JP2023577144
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-10-28
- Filing Date
- 2023-10-27
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing botulinum toxin formulations, particularly in dry powder form, face challenges with protein instability and require rehydration, leading to administration errors and deviations in toxin activity, necessitating the development of a stable liquid formulation that maintains activity over time.
A liquid formulation containing botulinum toxin with proline, optionally supplemented with sucrose, albumin, and other excipients, stabilizes the toxin for long-term storage and use without rehydration, ensuring consistent activity.
The formulation maintains botulinum toxin activity for extended periods, reducing administration errors and ensuring quantitative dosing, with stability at room temperature or refrigerated conditions.
Smart Images

Figure 2024542906000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a liquid preparation containing a botulinum toxin and proline, as well as a method for producing the same and uses thereof. [Background technology]
[0002] Botulinum toxin is a type of neurotoxin protein produced by bacteria such as Clostridium botulinum, which irreversibly attaches to presynaptic nerve terminals and inhibits the secretion of acetylcholine at the nerve junction, blocking muscle contraction and secondarily exerting a muscle relaxation effect. Due to this function, botulinum toxin has been used for therapeutic and cosmetic purposes since it was approved by the US FDA in 1989 (KR 10-2010-0107475 A, KR 10-2008-0049152 A, etc.).
[0003] It is used therapeutically as an injection for neuromuscular disorders such as strabismus, torticollis, or blepharospasm, and for cosmetic purposes to remove wrinkles, frown lines, and correct square jaws, as well as to treat hyperhidrosis or migraines. Although there have been reported cases of side effects such as dysphagia, voice change, dry mouth, and blurred vision, there have been no fatalities directly caused by botulinum toxin, and it is considered a very safe drug when used appropriately.
[0004] However, in the case of protein preparations such as botulinum toxin, many problems occur during the drug formulation process, which are particularly serious in the case of protein preparations such as botulinum toxin, which are formulated at extremely low concentrations due to protein instability.
[0005] Conventional commercial botulinum toxin preparations are prepared in the form of dry powder by lyophilization or vacuum drying in order to enhance the safety of the protein. However, in the case of dry powder preparations prepared by methods such as lyophilization, a rehydration process must be performed when used, which is inconvenient to use, and there is also a problem that deviations in the amount of botulinum toxin administered, particularly deviations in activity, occur due to errors in the dilution process during the rehydration process. Therefore, there is an increasing demand for liquid preparations that are convenient for users and can minimize errors in the rehydration process. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] KR 10-2010-0107475 A [Patent Document 2] KR 10-2008-0049152 A Summary of the Invention [Problem to be solved by the invention]
[0007] Since there is still a lack of development of a stable liquid preparation that can be stored for a long period of time while maintaining the activity of botulinum toxin for a long period of time, there is still a demand for development of a liquid preparation containing a botulinum toxin with a new composition. [Means for solving the problem]
[0008] It is an object of the present invention to provide a liquid formulation comprising a botulinum toxin and proline.
[0009] Another object of the present invention is to provide a method for producing the above liquid preparation.
[0010] Another object of the present invention is to provide a method for stabilizing a botulinum toxin using the above liquid formulation. Effect of the Invention
[0011] The liquid preparation of botulinum toxin according to the present invention is in a form that can be used immediately without the need for a rehydration process, which not only improves convenience for users but also reduces deviations in the activity of botulinum toxin due to dilution errors during the rehydration process and allows for fixed dose administration. In addition, the preparation has excellent storage stability in a liquid state, and the activity of botulinum toxin is maintained for a long period of time even at room temperature or under refrigerated conditions. [Brief description of the drawings]
[0012] [Figure 1] The figures show the results of evaluating the residual potency by type of excipient. [Diagram 2] 1 shows the results of evaluating the residual potency of combinations of excipients and disaccharides. [Diagram 3] The figure shows the results of evaluating the residual titer at different concentrations of proline and sucrose. [Figure 4] 1 shows the results of evaluating the residual titer according to the combination of excipient and albumin. [Diagram 5] 1 shows the results of evaluating the residual titer depending on the combination of excipient, disaccharide, and albumin. [Figure 6] The figure shows the results of evaluating the residual potency of a liquid preparation containing albumin at different concentrations of proline and sucrose. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0013] This will be described in detail as follows. Meanwhile, each description and embodiment disclosed in the present invention can be applied to each different description and embodiment. That is, all combinations of various elements disclosed in the present invention belong to the scope of the present invention. Also, the scope of the present invention is not limited by the following specific description.
[0014] Additionally, those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific embodiments of the invention described herein, and such equivalents are intended to be encompassed by the present invention.
[0015] One embodiment of the present invention provides a liquid formulation comprising a botulinum toxin and proline.
[0016] Specifically, the liquid formulation may be characterized by, but is not limited to, comprising botulinum toxin and proline; comprising botulinum toxin, sucrose, and proline; comprising botulinum toxin, albumin, and proline; comprising botulinum toxin, sucrose, albumin, and proline. The liquid formulation of the present invention may further comprise, but is not limited to, an isotonicity agent, a non-ionic surfactant, a buffer, or a combination thereof.
[0017] In the present invention, the term "liquid preparation" refers to a drug that has been formulated into a liquid form from a pharmaceutical product, and includes all liquid preparations for internal use and external use.
[0018] The liquid preparation of the present invention contains a substance that stably maintains and / or stores the pharmacologically effective botulinum toxin for a certain period of time when the botulinum toxin is formulated in liquid form. The components contained in the liquid preparation other than the pharmacologically effective botulinum toxin may be mixed with a stabilizer. In the present invention, the term "stabilizer" refers to a substance that stably maintains the components, such as the active ingredient, in the preparation for a certain period of time.
[0019] The liquid preparation of the present invention is characterized by containing a stabilizer composition that can stabilize the botulinum toxin so that the pharmacological effect of the botulinum toxin is maintained for a long period of time even when stored for a long period of time.
[0020] In the present invention, the term "botulinum toxin" is also referred to as "Clostridium botulinum toxin" and refers to a type of protein derived from Clostridium botulinum, which irreversibly attaches to presynaptic nerve terminals and inhibits the secretion of acetylcholine at nerve junctions, thereby blocking muscle contraction and secondarily exerting a muscle relaxant effect.
[0021] Botulinum toxin proteins have a molecular weight of about 150 kD and are divided into seven types, A through G, based on serological characteristics. Botulinum toxin type A is the most lethal natural substance known to humans, and in addition to serotype A, there are six other generally immunologically distinct botulinum toxins, namely botulinum toxin serotypes B, C, D, E, F, and G. The different serotypes can be distinguished by neutralization with type-specific antibodies and differ in the severity of the paralysis they induce and in the animal species they most affect.
[0022] The molecular weight of the botulinum toxin molecule is about 150 kD for all seven known botulinum toxin serotypes. However, botulinum toxins are released by clostridial bacteria as complexes containing the 150 kD botulinum toxin protein molecule along with associated non-toxin proteins. Thus, botulinum toxin type A complexes can be produced by clostridial bacteria as 900 kD, 500 kD and 300 kD forms. Botulinum toxin types B and C are 500 kD complexes, and botulinum toxin type D can be produced as 300 kD and 500 kD complexes. Botulinum toxin types E and F can be produced as about a 300 kD complex. The complexes (i.e., those with a molecular weight greater than about 150 kD) are believed to contain the non-toxic hemagglutinin protein and the non-toxin and non-toxic non-hemagglutinin proteins.
[0023] Botulinum toxins include the form of high molecular weight complexes that contain non-toxin proteins together with the pure neurotoxin component of about 150 kD. Thus, the complexed form can contain botulinum neurotoxin protein and one or more non-toxin hemagglutinin proteins and / or one or more non-toxin non-hemagglutinin proteins. Specifically, the botulinum toxin complex protein can be a complex of botulinum neurotoxin (BoNT), nontoxic nonhemagglutinin (NTNH), and hemagglutinin (HA) proteins. The molecular weight of the complex can be greater than about 150 kD. For example, the complexed form of botulinum toxin type A can have a molecular weight of about 900 kD, about 500 kD, or about 300 kD. The method of purifying Clostridium botulinum toxin complex of the present invention can purify the above various complexes.
[0024] In one embodiment, the botulinum toxin of the present invention can be a type A toxin.
[0025] As a specific example of any one of the above-mentioned embodiments, the botulinum toxin of the present invention may be in the form of a complex bound to a non-toxic protein. Specifically, the botulinum toxin complex protein of the present invention may be a complex of botulinum toxin (BoNT; Botulinum neurotoxin), nontoxic nonhemagglutinin (NTNH; nontoxic nonhemagglutinin), and hemagglutinin (HA; hemagglutinin) protein. More specifically, the botulinum toxin complex protein of the present invention may be a complex of BoNT, NTNH, hemagglutinin 70 (HA70), hemagglutinin 33 (HA33), and hemagglutinin 17 (HA17). More specifically, the HA70 is divided into HA20 (hemagglutinin 20) and HA50 (hemagglutinin 50), and the BoNT is divided into a light chain (LC: Light chain) of about 50 kD and a heavy chain (HC: Heavy chain) of about 100 kD, but is not limited thereto.
[0026] As an example of any one of the above-mentioned embodiments, the botulinum toxin complex protein of the present invention may have a molecular weight of more than 150 kD, more specifically, a molecular weight of about 250 kD to 1400 kD, more specifically, a molecular weight of 280 kD to 1300 kD, 300 kD to 1200 kD, 700 kD to 1100 kD, 800 kD to 1000 kD, or about 900 kD, but is not limited thereto.
[0027] The botulinum toxin of the present invention may include either one obtained from a Clostridium botulinum culture medium or one obtained commercially, and the botulinum toxin may be included so as to finally achieve a concentration of 100 units / ml, but is not limited thereto.
[0028] As used herein, the term "proline" refers to an amino acid which, for purposes of the present invention, helps to prolong the pharmacological effect of the botulinum toxin.
[0029] The liquid preparation of the present invention may contain the above-mentioned proline at a concentration of about 0.01 to 0.5% (w / v), about 0.05 to 0.5% (w / v), about 0.1 to 0.5% (w / v), about 0.1% (w / v), about 0.2% (w / v), about 0.3% (w / v), about 0.4% (w / v), or about 0.5% (w / v), but is not limited thereto.
[0030] As an example, it was confirmed that the liquid preparation of the present invention has the most excellent effect of maintaining the activity of botulinum toxin when proline is added to various excipients.
[0031] The liquid formulations according to the present invention may further comprise, but are not limited to, sucrose, which can increase the stability of the botulinum toxin in the liquid formulation.
[0032] The liquid preparation of the present invention contains the above-mentioned sucrose at a concentration of about 0.5 to 20% (w / v), about 0.5 to 15% (w / v), about 0.5 to 10% (w / v), about 0.5 to 8% (w / v), about 0.5 to 5% (w / v), about 0.5 to 4% (w / v), about 1 to 20% (w / v), about 1 to 15% (w / v), about 1 to 10% (w / v), about 1 to 8% (w / v), about 1 to 6% (w / v), or about 0.0% (w / v), about 1.0% (w / v), about 2.0% (w / v), about 3.0% (w / v), about 4.0% (w / v), about 5.0% (w / v), about 6.0% (w / v), or about 8.0% (w / v). % (w / v), but is not particularly limited thereto.
[0033] As an example, it was confirmed that the liquid preparation of the present invention, when sucrose was further added to proline, exhibited a residual potency of 90% or more for 10 weeks under accelerated conditions at 37° C. This suggests that the combination of proline and sucrose in a liquid preparation containing a botulinum toxin can act as a stabilizer to store the botulinum toxin in the liquid preparation for a long period of time without a decrease in potency.
[0034] The liquid preparation according to the present invention may further include albumin. Albumin is a type of protein, and is known as a plasma protein that transports various substances, including metal ions, drugs, and foreign organisms, and is known to be involved in regulating the pH and maintaining the osmotic pressure of the culture environment. In the present invention, the albumin may be, but is not limited to, Human Serum Albumin (HSA) obtained by extraction from human plasma or serum, or Recombinant Human Serum Albumin (rHSA) produced by recombination. Specifically, the albumin may be, but is not limited to, animal-derived HSA or plant-derived recombinant HSA. Recombinant albumin has the advantage of being free of blood-borne contaminants and capable of using only defined substances, and therefore has low immunogenicity.
[0035] The liquid preparation of the present invention may contain the above-mentioned albumin at a concentration of about 0.01-1% (w / v), about 0.05-1% (w / v), about 0.1-1% (w / v), about 0.1-0.8% (w / v), about 0.2-0.7% (w / v), about 0.3-0.6% (w / v), about 0.3% (w / v), about 0.4% (w / v), about 0.5% (w / v), or about 0.6% (w / v), but is not limited thereto.
[0036] A specific example of the liquid preparation according to the present invention may contain botulinum toxin and proline, and a more specific example is a liquid preparation containing 100 Unit / ml of botulinum toxin and 0.01 to 0.5% (w / v) of proline.
[0037] The liquid preparation according to the present invention may further contain sucrose. A specific example of the liquid preparation according to the present invention may contain botulinum toxin, sucrose, and proline, and a more specific example of the liquid preparation may be a liquid preparation containing 100 Unit / ml of botulinum toxin, 0.5 to 20% (w / v) sucrose, and 0.01 to 0.5% (w / v) proline.
[0038] The liquid preparation according to the present invention may further contain albumin. A specific example of the liquid preparation according to the present invention may contain botulinum toxin, albumin, and proline, and a more specific example of the liquid preparation may be a liquid preparation containing 100 Unit / ml of botulinum toxin, 0.01 to 1% (w / v) of albumin, and 0.01 to 0.5% (w / v) of proline.
[0039] Another specific example may contain botulinum toxin, sucrose, albumin, and proline, and a more specific example is a liquid preparation containing 100 Unit / ml of botulinum toxin, 0.5 to 20% (w / v) sucrose, 0.01 to 1% (w / v) albumin, and 0.01 to 0.5% (w / v) proline, but the liquid preparation of the present invention is not limited to the above examples.
[0040] The liquid formulation of the present invention may further comprise a non-ionic surfactant and / or a tonicity agent.
[0041] The nonionic surfactant can reduce the surface tension of a protein solution and prevent the protein from being adsorbed or aggregated on a hydrophobic surface.
[0042] Specific examples of the nonionic surfactant used in the present invention include polysorbates (e.g., polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate), polysorbate 40 (polyoxyethylene (20) sorbitan monopalmitate), polysorbate 60 (polyoxyethylene (20) sorbitan monostearate), polysorbate 80 (polyoxyethylene (20) sorbitan monooleate; the number (20) after the polyoxyethylene group refers to the total number of oxyethylene groups (-(CH2CHO)-)), poloxamer (PEO-PPO-PEO copolymer; PEO: poly(ethylene oxide), PPO: poly(propylene)), and the like. oxide), polyethylene-polypropylene glycol, polyoxyethylene compounds (e.g., polyoxyethylene-stearate, polyoxyethylene alkyl ether (alkyl: C1-C30), polyoxyethylene monoallyl ether, alkylphenyl polyoxyethylene copolymer (alkyl: C1-C30), etc.), sodium dodecyl sulphate (SDS), etc., and also include polysorbate or poloxamer, which may be used alone or in combination of two or more thereof.
[0043] Specifically, the nonionic surfactant may be poloxamer 188, polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80, or a combination of these may be used, but is not limited thereto.
[0044] In the present invention, the nonionic surfactant may be contained in the liquid preparation of the present invention at a concentration of about 0.2% (w / v) or less, for example, about 0.001 to about 0.2% (w / v), about 0.001 to about 0.1% (w / v), about 0.005 to about 0.1% (w / v), about 0.001 to about 0.08% (w / v), about 0.002 to about 0.08% (w / v), about 0.005 to about 0.05% (w / v), about 0.01 to about 0.05% (w / v), or about 0.05% (w / v), but is not particularly limited thereto.
[0045] The above-mentioned isotonicity agent is a substance added to adjust the osmotic pressure of a liquid preparation, and as long as it can contribute to stabilizing botulinum toxin while maintaining an appropriate osmotic pressure, it may be included in the liquid preparation of the present invention as an isotonicity agent without limitation.
[0046] The isotonicity agent may include a water-soluble inorganic salt. Specifically, the liquid formulation of the present invention may include, but is not limited to, any one or more isotonicity agents selected from the group consisting of sodium chloride, glycerin, potassium chloride, and dextrose.
[0047] In the present invention, the above-mentioned isotonicity agent may be contained in the liquid preparation of the present invention at a concentration of about 5% (w / v) or less, for example, about 0.01 to about 5% (w / v), about 0.1 to about 5% (w / v), about 0.1 to about 3% (w / v), about 0.1 to about 2% (w / v), about 0.5 to about 1.5% (w / v), about 0.75 to about 1.25% (w / v), or about 0.9% (w / v), but is not particularly limited thereto.
[0048] The liquid formulation of the present invention may further include a buffering agent. For example, the buffering agent may be any one or more selected from the group consisting of acetic acid and its salts, citric acid and its salts, and phosphoric acid and its salts, and examples thereof include, but are not limited to, phosphoric acid and its salts (e.g., phosphate, sodium phosphate, potassium phosphate, or hydrogen or dihydrogen salts thereof), citric acid and its salts (e.g., sodium citrate), acetic acid and its salts (e.g., sodium acetate), or sodium phosphate.
[0049] In the present invention, the above-mentioned buffer is added to the liquid preparation of the present invention at a concentration of about 5.0% (w / v) or less, about 4.0% (w / v) or less, about 3.0% (w / v) or less, about 2.0% (w / v) or less, about 1.0% (w / v) or less, about 0.9% (w / v) or less, about 0.8% (w / v) or less, for example, about 0.01 to about 5.0% (w / v), about 0.01 to about 4.0% (w / v), about 0.01 to about 3.0% (w / v), about 0.01 to about 2.0% (w / v), about 0.0 The concentration may be, but is not limited to, 1 to about 1.0% (w / v), about 0.01 to about 5.0% (w / v), about 0.1 to about 1.0% (w / v), about 0.01 to about 0.9% (w / v), about 0.05 to about 0.9% (w / v), about 0.1 to about 1.00% (w / v), about 0.4 to about 0.9% (w / v), about 0.4 to about 2.0% (w / v), about 0.3 to about 1.0% (w / v), about 0.3 to about 0.8% (w / v), or about 0.05% (w / v), or about 0.7% (w / v).
[0050] The liquid formulations of the present invention may include pharma- ceutically acceptable salt forms.
[0051] The term "pharmaceutical acceptable" means, within the scope of medical judgment, a substance that can be effectively used for a desired purpose without inducing excessive toxicity, irritation, allergic response, or the like.
[0052] The term "pharmaceutical acceptable salts" as used herein includes salts derived from pharmaceutical acceptable inorganic acids, organic acids, or bases. Examples of suitable acids include hydrochloric acid, bromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-p-sulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, and the like. Salts derived from suitable bases can include alkali metals such as sodium, potassium, alkaline earth metals such as magnesium, and ammonium, and the like.
[0053] Furthermore, the liquid formulation according to the present invention may further contain a pharma- ceutically acceptable carrier, excipient, etc., and such a carrier or excipient may be non-naturally occurring.
[0054] Specifically, the term "pharmaceutical acceptable carrier" refers to a carrier or diluent that does not stimulate living organisms and does not inhibit the properties of the liquid formulation of the present invention. Pharmaceutical carriers acceptable for compositions formulated into liquid solutions include, as sterilized and biocompatible carriers, saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and mixtures of one or more of these components, and other common additives such as antioxidants, buffers, bacteriostatic agents, etc. can be added as necessary.
[0055] More specifically, carriers, excipients and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, polycaprolactone, polylactic acid, poly-L-lactic acid, mineral oil and the like.
[0056] The liquid preparation of the present invention is used for the treatment or prevention of diseases that can be prevented, treated, or ameliorated by administration of a botulinum toxin, such as neuromuscular disorders characterized by hyperactive skeletal muscles. It is also used for the treatment or prevention of headaches, migraines, tension headaches, sinus headaches, cervicogenic headaches, sweating disorders, armpit hyperhidrosis, hand hyperhidrosis, foot hyperhidrosis, Frey's syndrome, hyperkinetic skin wrinkles, and the like. It is used for various purposes such as, but not limited to, the treatment of diseases such as facial wrinkles, glabellar lines, crow's feet, mouth wrinkles, nasolabial lines, skin disorders, aschalasis, strabismus, chronic anal fissures, blepharospasm, musculoskeletal pain, fibromyalgia, pancreatitis, tachycardia, prostatic hyperplasia, prostatitis, urinary retention, urinary incontinence, overactive bladder, hemifacial spasm, tremors, muscle spasms, gastrointestinal disorders, diabetes, hypersalivation, detrusor-sphincter dyssynergia, post-stroke rigidity, wound healing, pediatric cerebral palsy, smooth muscle spasms, restenosis, regional dystonia, epilepsy, cervical dystonia, thyroid disorders, hypercalcemia, obsessive-compulsive disorder, arthritis pain, Raynaud's syndrome, stretch marks, peritoneal adhesions, vasospasm, runny nose, muscle spasms, laryngeal dystonia, writer's cramp, and carpal tunnel syndrome, as well as cosmetic purposes.
[0057] In the present invention, the term "prevention" refers to any action of suppressing a disease by administering the above-mentioned botulinum toxin or a liquid preparation containing it, or suppressing or delaying the onset of a disease by administering a liquid preparation, and the term "treatment" in the present invention refers to any action of improving, reversing or providing benefit to the symptoms of a target disease by administering a botulinum toxin or a liquid preparation containing it.
[0058] In a specific embodiment of the present invention, the liquid formulation of the present invention may be utilized for the treatment or prevention of neuromuscular disorders, but is not limited thereto.
[0059] Furthermore, the liquid preparation of the present invention may have a dosage form and composition suitable for subcutaneous administration, and may be administered via a subcutaneous route, but is not limited thereto.
[0060] As used herein, the term "administration" refers to the introduction of a liquid formulation into a patient by any suitable method, which may be, for example, but is not limited to, intramuscular administration, subcutaneous administration, and the like.
[0061] The total dosage of the liquid preparation of the present invention may be about 0.0001 mg to 500 mg per kg of patient body weight per day, and the liquid preparation may be formulated so that the above dosage can be appropriately administered. However, the dosage of the botulinum toxin is determined by taking into consideration various factors such as the administration route and number of treatments as well as the patient's age, body weight, health condition, sex, severity of disease, diet, and excretion rate, and therefore, when considering these points, a person having ordinary knowledge in the art can determine an appropriate effective dosage for a specific use of the liquid preparation of the present invention.
[0062] In the present invention, the term "about" includes not only the exact number described after the term, but also an approximate number or a range close to the number. Whether the number is close to or approximately the specific number mentioned can be determined by considering the context in which the number is presented. As an example, the term "about" can refer to a range of -10% to +10% of a numerical value. In another example, the term "about" can refer to a range of -5% to +5% of a given numerical value. However, it is not limited thereto.
[0063] Another embodiment of the present invention provides a method for producing the liquid formulation.
[0064] Specifically, the method may include, but is not limited to, mixing botulinum toxin and proline together, and may further include mixing albumin, sucrose, or both.
[0065] Another embodiment of the present invention provides a method for stabilizing a botulinum toxin using the liquid formulation.
[0066] The liquid formulation may further comprise one or more components selected from the group consisting of, but not limited to, sucrose, albumin, an isotonicity agent, a non-ionic surfactant, and a buffering agent.
[0067] The liquid preparation and its constituent elements are as described above.
[0068] In the case of protein preparations such as the botulinum toxin of the present invention, many problems occur during the drug formulation process. This problem is particularly severe in the case of proteins such as botulinum toxin, which are drugged at very low concentrations due to the instability of the protein. Since botulinum toxin is highly toxic and must be administered in very small amounts for therapeutic or cosmetic use, low-concentration liquid formulations of botulinum toxin are preferred over high-concentration liquid formulations of botulinum toxin.
[0069] In view of the above, there is a strong demand for a new type of liquid preparation capable of maintaining a constant activity of botulinum toxin. The liquid preparation of the present invention can maintain the activity of botulinum toxin even after long-term storage and has excellent dosage stability.
[0070] The present invention will be described in more detail with reference to the following examples and experimental examples. However, these examples and experimental examples are provided for illustrative purposes only and the scope of the present invention is not limited to these examples and experimental examples.
[0071] Example 1. Preparation of a liquid preparation of botulinum type A toxin A liquid preparation of botulinum type A toxin (molecular weight approximately 900 kD) was prepared in the following manner. Sodium phosphate 50 mmol was added as a buffer, sodium chloride 0.9% as an isotonicity agent, and polysorbate 20 as a surfactant at a concentration of 0.05% (w / v). Each excipient was added to the buffer containing botulinum type A toxin, the isotonicity agent, and the surfactant according to the corresponding concentration, and mixed and dissolved homogeneously. The pH was adjusted to 6.0, and the solution was filtered through a 0.22 μm filter. A botulinum toxin liquid preparation was prepared using the filtered solution to a final concentration of 100 Units / ml (Table 1).
[0072] [Table 1]
[0073] The excipient candidates were added at the concentrations shown in Table 2 below. The following excipient candidates were added at concentrations adjusted based on the maximum content of additives announced by the Food and Drug Administration.
[0074] [Table 2]
[0075] Example 2. Evaluation of the stability of botulinum type A toxin To evaluate the stability of the botulinum toxin liquid preparation prepared in Example 1, an ELISA method using an anti-SNAP25 antibody was used to confirm the effect on SNAP25 cleavage under accelerated conditions at 37°C, and the toxin titer was calculated based on the result. The prepared botulinum toxin liquid preparation was stored under accelerated conditions at 37°C, and samples were taken at regular intervals (1 week) to confirm the change in toxin titer depending on storage time.
[0076] ELISA was performed as follows. The liquid preparation to be assayed and recombinant SNAP25 (Abcam, USA) were mixed at a ratio of 100:1, and the enzyme reaction was carried out in a chamber at 37°C. After 21 hours, the liquid preparation-SNAP25 mixture was taken out and mixed at a ratio of 1:1 with coating buffer (100 mM bicarbonate / carbonate, pH 9.6) containing 10 mM EDTA (ethylene-diamine-tetraacetic acid), and then 100 ul was dispensed into each well of a 96-well plate (Thermo, USA) and coated at room temperature for 2 hours. After coating, the plate was washed three times with washing buffer (Thermo, USA) and blocked at room temperature for 2 hours using 5% skim milk. The plate was then washed three times with washing buffer, and 100 ul of specific antibody against cleaved SNAP25 (mybiosource, USA) diluted in 5% skim milk was dispensed into each well and reacted at room temperature for 2 hours. After washing three times with washing buffer, the plate was incubated with HRP-conjugated secondary antibody (Abcam, USA) diluted in 5% skim milk at room temperature for 2 hours. After the incubation, the plate was washed three times with washing buffer, and 100 ul of TMB Substrate solution (Thermo, USA) was dispensed into each well to induce color reaction. The reaction was stopped by adding an equal amount of 2N sulfuric acid (Sigma, USA), and the absorbance was measured at 450 nm using an absorbance analyzer (BioTek, USA). The measured values were used to express the toxin titer as a percentage using the values of the positive and negative controls. The toxin titer was calculated using the following formula:
[0077] Toxic titer (%) = (color development value of the liquid preparation to be tested experimental group - color development value of the experimental group not treated with toxin) / (color development value of the experimental group treated only with 100 Unit / ml BoNT / A stock solution - color development value of the experimental group not treated with toxin) x 100
[0078] Example 3. Evaluation of stabilizers for liquid formulations of botulinum type A toxin An experiment was carried out to evaluate the potency of the liquid preparation of botulinum type A toxin of Example 1 above under accelerated conditions at 37° C. at weekly intervals using the method of Example 2.
[0079] 3-1. Evaluation of residual potency by type of excipient The residual potency of each type of excipient was evaluated. Specifically, the excipients used were meglumine + glutamic acid, N-acetylcysteine, proline, taurine, glutathione, or PEG3350, and the concentrations of the excipients contained in the liquid formulation of botulinum toxin are as shown in Table 2 above.
[0080] As a result, as shown in FIG. 1, it was confirmed that proline maintained a residual potency of 90% or more for more than 6 weeks among the excipients, and it was found that the above excipients have the best effect of maintaining the activity of botulinum toxin.
[0081] 3-2. Evaluation of residual titer by combination of disaccharides In order to confirm whether the residual potency is excellent even when a disaccharide is added, the residual potency was evaluated by further adding a disaccharide to the excipient of Example 3-1.
[0082] Specifically, the disaccharides used were sucrose, lactose, and a combination thereof.
[0083] As a result, as shown in FIG. 2, it was confirmed that the combination of proline and sucrose showed the best residual titer of 90% or more for 10 weeks under accelerated conditions at 37° C.
[0084] The above results reaffirm that the combination of proline and sucrose in a composition containing botulinum toxin can serve as a stabilizer to preserve the botulinum toxin in a liquid formulation for a long period of time without a decrease in potency.
[0085] 3-3. Evaluation of residual titer depending on sucrose concentration Through the above Example 3-2, it was confirmed that the combination of proline and sucrose was the most effective stabilizer, and the residual potency was evaluated according to the proline and sucrose concentrations.
[0086] Specifically, proline was used at 0.1% to 0.3% (w / v), and sucrose was used at 0% to 8% (w / v).
[0087] As a result, as shown in Table 3 and Figure 3 below, it was confirmed that a combination of 0.2% to 0.3% (w / v) proline and 4% to 8% (w / v) sucrose showed a residual titer of 90% or more for 10 weeks under accelerated conditions at 37°C.
[0088] [Table 3]
[0089] 3-4. Evaluation of residual titer with combination of rHSA and excipients In order to confirm whether the residual titer is excellent even when rHSA is included, the residual titer was evaluated by further adding rHSA to the excipient of Example 3-1.
[0090] As a result, as shown in FIG. 4, it was confirmed that the combination of rHSA and proline showed the best residual titer of 90% or more for 10 weeks under accelerated conditions at 37° C.
[0091] The above results suggest that the combination of rHSA and proline in a composition containing botulinum toxin can act as a stabilizer to preserve the botulinum toxin in a liquid formulation for a long period of time without a decrease in potency.
[0092] 3-5. Evaluation of residual titer following combination of rHSA and disaccharides Based on the results of Examples 3-2 and 3-4 above, it was confirmed that the combination of rHSA and disaccharides maintained safety for a long period of time, and liquid preparations were prepared to compare the residual titers of different types of disaccharides.
[0093] Specifically, the disaccharides used were sucrose and lactose.
[0094] As a result, as shown in FIG. 5, it was confirmed that the combination of rHSA, proline and sucrose showed the best residual titer of 90% or more for 10 weeks under accelerated conditions at 37° C.
[0095] The above results reaffirm that the combination of rHSA, proline and sucrose in a composition containing botulinum toxin can serve as a stabilizer to preserve the botulinum toxin in a liquid formulation for a long period of time without a decrease in potency.
[0096] 3-6. Evaluation of the residual titer of liquid preparations containing rHSA depending on the sucrose concentration Through the above Examples 3-5, it was confirmed that the combination of rHSA, proline and sucrose was the most effective stabilizer, and the residual potency was evaluated according to the proline and sucrose concentrations.
[0097] Specifically, proline was used at 0.1% to 0.3% and sucrose was used at 0% to 8% in a liquid preparation containing rHSA.
[0098] As a result, as shown in Table 4 and Figure 6 below, it was confirmed that a combination of 0.2% to 0.3% proline and 4% to 8% sucrose showed a residual titer of approximately 80% or more for 10 weeks under accelerated conditions at 37°C.
[0099] [Table 4]
[0100] From the above description, a person skilled in the art to which the present invention pertains will understand that the present invention can be implemented in other specific forms without changing its technical idea or essential features. In this regard, it should be understood that the above-described embodiments are merely illustrative and not limiting. The scope of the present invention should be interpreted as including any modified or altered forms derived from the meaning and scope of the claims below, and their equivalent concepts, rather than the above detailed description.
Claims
1. A liquid formulation comprising a botulinum toxin and proline.
2. 2. The liquid formulation of claim 1, wherein the botulinum toxin is botulinum toxin type A.
3. The liquid formulation according to claim 1, wherein the proline is contained in an amount of 0.01 to 0.5% (w / v) based on the total liquid formulation.
4. The liquid formulation of claim 1 , further comprising sucrose.
5. The liquid formulation according to claim 4, wherein the sucrose is present in an amount of 0.5 to 20% (w / v) based on the total liquid formulation.
6. The liquid formulation of claim 1 , further comprising albumin.
7. The liquid formulation of claim 6 , wherein the albumin is a recombinant albumin.
8. The liquid preparation according to claim 6, wherein the albumin is contained in an amount of 0.01 to 1% (w / v) based on the total liquid preparation.
9. 10. The liquid formulation of claim 1, further comprising a non-ionic surfactant and a tonicity agent.
10. The liquid formulation according to claim 9, wherein the non-ionic surfactant is at least one selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80 and polysorbate 100.
11. 2. The liquid formulation of claim 1, further comprising a non-ionic surfactant at a concentration of 0.005-0.1% (w / v).
12. 10. The liquid preparation according to claim 9, wherein the isotonicity agent is any one or more selected from the group consisting of sodium chloride, glycerin, potassium chloride, and dextrose.
13. The liquid formulation 100 Units / ml of botulinum toxin, and 2. The liquid formulation of claim 1, comprising 0.01 to 0.5% (w / v) proline.
14. The liquid formulation 100 Units / ml of botulinum toxin; 0.01 to 0.5% (w / v) proline, and 2. The liquid formulation of claim 1, comprising 0.01 to 1% (w / v) albumin.
15. The liquid formulation 100 Units / ml of botulinum toxin; 0.01 to 0.5% (w / v) proline, and 2. The liquid formulation of claim 1, comprising 0.5 to 20% (w / v) sucrose.
16. The liquid formulation 100 Units / ml of botulinum toxin; 0.01 to 0.5% (w / v) proline, 0.01-1% (w / v) albumin, and 2. The liquid formulation of claim 1, comprising 0.5 to 20% (w / v) sucrose.
17. A method for stabilizing a botulinum toxin using a liquid formulation containing a botulinum toxin and proline.
18. 20. The method of claim 17, wherein the liquid formulation further comprises albumin, sucrose, or both.
Citation Information
Patent Citations
Botulinus toxin formulation capable of high-dose administration
JP2011157331A
Stable liquid compositions containing botulinum toxin
JP2020505382A
Stabilized liquid composition of botulinum toxin
JP2022509150A
Stable Liquid Composition Comprising Botulinum Toxin
KR101744900B1
Therapeutic composition with a botulinum neurotoxin
KR1020080049152A
